Regional CBF changes in Parkinson's disease: The importance of functional neuroimaging analyses

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1455-1457

  Amorim, Bárbara J ^a   Camargo, Erica C S ^b   Etchebehere, Elba C S C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

BRADYKINESIA; BRAIN PERFUSION; CEREBELLUM; CINGULATE GYRUS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; GLOBUS PALLIDUS; HUMAN; INDEPENDENT COMPONENT ANALYSIS; MUSCLE RIGIDITY; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREFRONTAL CORTEX; PUTAMEN; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

AGED; BRAIN; CEREBROVASCULAR CIRCULATION; DIAGNOSTIC IMAGING; HUMANS; MODELS, STATISTICAL; PARKINSON DISEASE; PERFUSION; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 34548161660     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0411-8     Document Type: Note

References (13)

1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86.
2. Hsu JL, Jung TP, Hsu CY, Hsu WC, Chen YK, Duann JR, et al. Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction. Eur J Nucl Med Mol Imaging 2007; DOI 10.1007/s00259-006-0360-7.
3. Sawada H, Udaka F, Kameyama M, Seriu N, Nishinaka K, Shindou K, et al. SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992;55:960-3.
4. 123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia. Intern Med 2005;44:1046-50.
5. m-HMPAO SPECT in Parkinson's disease. Nucl Med Commun 1992;13:744-8.
6. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001;22:45-6.
7. Derejko M, Slawek J, Wieczorek D, Brochhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun 2006;27:945-51.
8. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003;20:1309-19.
9. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005;107:396-403.
10. Feigin A, Antonini A, Fukada M, De Notaris R, Benti R, Pezzoli G, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002;17:1265-70.
11. 99mTc-ECD brain perfusion SPECT allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2003;30:16-24.
12. Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. J Neurol Neurosurg Psychiatry 1994;57:180-5.
13. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 1999;40:1583-9.